纳洛塞醇(Naloxegol Oxalate) - 药物靶点：μ opioid receptor_在研适应症：便秘，阿片类药物引起的便秘_专利_临床

概要

基本信息

药物类型

小分子化药

别名

(5α,6α)-17-Allyl-6-[(20-hydroxy-3,6,9,12,15,18-hexaoxaicos-1-yl)oxy]-4,5-epoxymorphinan-3,14-diol、naloxegol、Naloxegol oxalate (USAN)

+ [9]

靶点

μ opioid receptor

作用方式

拮抗剂

作用机制

μ opioid receptor拮抗剂(μ-阿片受体拮抗剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

AccelagenAveritas Pharma, Inc.

+ [1]

非在研机构

AstraZeneca PLCKyowa Kirin Pharmaceutical Development Ltd.Kyowa Kirin Holdings BV

权益机构

Nektar Therapeutics

Knight Orthodontics

RedHill Biopharma Ltd.

+ [8]

最高研发阶段批准上市

首次获批日期

美国 (2014-09-16),

阿片类药物引起的便秘

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C36H55NO15

InChIKeyMNYIRXLCPODKLG-VUTNLTPYSA-N

CAS号1354744-91-4

关联

45

项与纳洛塞醇相关的临床试验

NCT04219046

/ Withdrawn临床2期IIT

Evaluation of Naloxegol, a Peripherally Acting µ-opioid Receptor Antagonist, in the Prevention of Postoperative Ileus After Cystectomy

Postoperative ileus (POI) is defined as a transient reduction of bowel motility that prevents effective transit of bowel content and tolerance of oral intake following surgical interventions, especially after radical cystectomy. It remains a major factor associated with postoperative morbidity, length of hospital stay and medical costs.
In order to optimize perioperative care for patients undergoing radical cystectomy in a context of an ERAS (Enhanced Recovery After Surgery) program, we will evaluate the effectiveness of systemic pharmacologic opioid antagonist treatment.

开始日期2032-01-01

申办/合作机构

Institut Jean Paoli & Irene Calmettes

CTIS2024-512673-28-00

/ Not yet recruiting临床4期

Double-blind placebo-controlled cross-over MRI study to evaluate the effect of naloxegol and codeine on gastrointestinal motility and volumes

开始日期2024-10-28

申办/合作机构

UZ Leuven

NCT05008926

/ Suspended临床3期IIT

The NIPA Study: A Randomized Double-blind Control Clinical Trial Naloxegol Administration to Prevent Opioids Induced Gastrointestinal Motility Disturbance in Brain Injured PAtients

Impaired gastrointestinal transit (IGT) especially constipation, is common among patients under mechanical ventilation, occurring in up to 80 % of the patients during the first week, and has been associated with worse outcome in intensive care unit (ICU). Although IGT in critically ill patients is multifactorial and some components are due to complex disease, there is increasing evidence that exogenous opioids contribute to bowel dysmotility.
Sedatives and especially opioids are largely used in the brain injured population to control intracranial pression, reduce metabolic rate, manage or prevent seizures, and improve mechanical ventilator synchrony. Therefore, brain injured patients are particularly at risk to develop IGT. The occurrence of IGT is associated with adverse outcomes in intensive care unit. Both gastric reflux and impaired peristaltic contractions are associated with ventilator-acquired pneumonia.
The actual challenge is to prevent motility disorders before it occurs. A preventive strategy could in turn reduce the occurrence of complications related to impaired gastrointestinal transit such as ventilator-acquired pneumonia, bacteremia etc. It could also reduce the complications of feed intolerance and thus reduce morbidity and mortality in ICU.
Naloxegol is a polyethylene glycol derivative of naloxol, which is a derivative of naloxone and a peripherally acting µ-opioid receptor antagonist. Contrary to naloxone, naloxegol has a very low penetration into the central nervous system, therefore it could be a relevant option for ileus prevention without the risk of impaired sedation.
The aim of our study is to assess the efficacy of the administration of naloxegol on the onset of early constipation and early ventilator-acquired pneumonia in brain injured patients receiving opioids for analgosedation.

开始日期2022-03-15

申办/合作机构

University Hospital of Brest

100 项与纳洛塞醇相关的临床结果

登录后查看更多信息

100 项与纳洛塞醇相关的转化医学

登录后查看更多信息

100 项与纳洛塞醇相关的专利（医药）

登录后查看更多信息

171

项与纳洛塞醇相关的文献（医药）

2026-09-01·Translational Andrology and Urology

Peripherally acting μ-opioid receptor antagonists for recovery of bowel function after radical cystectomy: a systematic review and meta-analysis

Article

作者: Hayne, Dickon ; McDonald, Sam ; Lim, Jayne ; Powell, Emma

Background:

Postoperative ileus (POI) is common after radical cystectomy (RC) and contributes to prolonged hospital stay, increased healthcare costs, and reduced patient quality of life. Peripherally acting μ-opioid receptor antagonists (PAMORAs), including alvimopan, naloxegol, and methylnaltrexone, have been investigated as strategies to reduce POI while preserving opioid-mediated analgesia. Previous systematic reviews have shown benefit of PAMORAs, particularly alvimopan, in abdominal procedures such as bowel resection and hysterectomy, but evidence specific to RC remains heterogeneous and limited. We aimed to evaluate whether incorporation of PAMORAs (alvimopan, naloxegol, or methylnaltrexone) into enhanced recovery pathways reduces POI compared with enhanced recovery pathways alone in patients undergoing RC.

Methods:

A literature search of PubMed, MEDLINE, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) was conducted to identify studies evaluating PAMORAs for prevention of POI following RC. Search terms included alvimopan, naloxegol, methylnaltrexone, and RC. Eligible study designs included randomized controlled trials (RCTs), non-randomized trials, and observational studies comparing PAMORAs with placebo or standard care. Two independent reviewers extracted data using Covidence software. Outcomes included time to gastrointestinal recovery, time to first flatus, time to first bowel movement, length of stay (LOS), POI incidence, adverse events (including cardiovascular events), and costs. Results were summarized in a Summary of Findings table.

Results:

Across included studies, PAMORAs were associated with improved postoperative gastrointestinal recovery, although certainty of evidence varied. PAMORAs shortened time to first flatus by approximately 1 day [mean difference (MD) =-0.97 days; 95% confidence interval (CI): -1.07 to -0.87] across six observational studies with no detectable heterogeneity (I²=0%), but certainty of evidence was very low due to non-randomized designs and risk of bias. Time to first bowel movement was reduced by approximately 1.3 days (MD =-1.30 days; 95% CI: -1.81 to -0.79) across nine studies, although substantial heterogeneity was observed (I²=84%).

Conclusions:

PAMORAs appear to improve postoperative gastrointestinal recovery following RC. However, overall certainty of evidence remains low due to reliance on non-randomized studies and heterogeneity. Alvimopan has the strongest supporting evidence, while data for naloxegol and methylnaltrexone remain limited.

2026-07-03·Expert Opinion On Drug Safety

Post-marketing safety assessment of constipation drugs: a real-world pharmacovigilance study based on FAERS database

Article

作者: Yang, Shiwei ; Zhang, Guang ; Xin, Xuezhi ; Zhang, Wenyu ; Hu, Wenqi ; Wang, Hui ; Pang, Xue

BACKGROUND:

Laxatives are widely used in the treatment of constipation, but they also have brought many adverse reactions to patients.

METHODS:

We conducted a pharmacovigilance analysis based on the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database to analyze the adverse events of six constipation drugs (linaclotide, lubiprostone, prucalopride, naloxegol, naldemedine, and plecanatide) and to search for clinically meaningful adverse reaction signals. We used disproportionality analysis as the main analysis method to detect pharmacovigilance signals, which includes Frequentist methods and Bayesian methods.

RESULTS:

Among the reports of the six drugs, more adverse reactions were reported from females than males, and the number of adverse reactions reported was higher in the group of 60-89 years. Linaclotide had the lowest proportion of serious adverse event reports (4.38%), while naldemedine had the highest proportion of serious adverse event reports (25.57%). According to the classification of system organ classification (SOC), the number of gastrointestinal adverse events (N = 8321) was the largest.

CONCLUSIONS:

The adverse reactions of constipation drugs were mainly gastrointestinal symptoms such as diarrhea, abdominal pain and abdominal distension. Linaclotide has the highest safety, and more studies are needed to analyze the cardiovascular safety of lubiprostone.

2026-06-01·Clinical Journal of Oncology Nursing

Peripherally Acting Mu-Opioid Receptor Antagonist Use in Opioid-Induced Constipation in Patients With Cancer: A Scoping Review

Article

作者: Yu, Jie

BACKGROUND:

Opioid-induced constipation (OIC) is a common and debilitating gastrointestinal side effect among adult patients with cancer receiving opioid therapy for pain management. Peripherally acting mu-opioid receptor antagonists (PAMORAs) have emerged as a promising treatment option.

OBJECTIVES:

This scoping review evaluates the current evidence regarding the efficacy and safety of three U.S. Food and Drug Administration-approved PAMORAs-naldemedine, naloxegol, and methylnaltrexone-in managing OIC in adult patients with cancer.

METHODS:

A literature search was conducted using PubMed®, CINAHL®, and Scopus® databases. Eight studies met the inclusion criteria and were analyzed.

FINDINGS:

PAMORAs effectively improved bowel movement frequency and enhanced constipation-related symptom relief and quality of life. Most adverse effects were gastrointestinal in nature but were generally mild to moderate in severity. Naloxegol and naldemedine were shown to be effective for long-term OIC management, and methylnaltrexone was effective for short-term relief.

86

项与纳洛塞醇相关的新闻（医药）

2026-09-23

·医药代表

拜耳重磅抗肿瘤药出售，买家定了！

一款老药，拜耳卖了将近 29 亿元！ 9 月 21 日，总部位于德国亚琛的格兰泰公司宣布，已与拜耳达成协议，将以最高 3.75 亿欧元（约 28.66 亿元人民币）的价格收购其旗下抗肿瘤药物拜万戈。据公告，此次收购尚需满足惯例交割条件，包括获得相关监管机构的批准，预计将于 2026 年底或 2027 年初完成。拜万戈（Stivarga，瑞戈非尼）是拜耳开发的一款口服多激酶抑制剂，用于治疗符合相应既往治疗条件的转移性结直肠癌、胃肠道间质瘤及肝细胞癌患者。该药于 2012 年 9 月首次在美国获批，用于治疗转移性结直肠癌，随后于 2013 年 2 月和 2017 年 4 月在美国新增胃肠道间质瘤、肝细胞癌适应症，并于 2013 年 8 月首次获得欧盟上市许可。在中国，拜万戈于 2017 年 3 月同时获批转移性结直肠癌和胃肠道间质瘤两项适应症，同年 12 月再获批用于既往接受过索拉非尼治疗的肝细胞癌患者，2018 年 3 月，拜耳宣布该肝癌适应症在华上市。据此次收购公告，拜万戈目前已在全球 90 多个市场获批并上市。对于 MRCLUB 的小伙伴们来说，更关心的可能是，中国市场会不会受到影响？据英文医药媒体 Fierce Pharma 报道，拜耳发言人向其表示，此次交易对员工的影响很小，公司将与格兰泰密切合作，按照当地适用要求，通过正常的业务过渡程序处理相关事宜。不过，这一回应针对的是整笔交易，对于中国市场，关注拜耳的小伙伴们应该知道，拜万戈的推广安排，早已发生变化（见 MRCLUB 历史消息：又有两款硬核原研药，内企接棒推广）。去年 3 月 6 日，亿帆医药宣布与拜耳签订商业化合作协议，获得拜万戈及多吉美（Nexavar，索拉非尼）在中国大陆地区的独家市场推广权益。可以这么理解，去年是中国大陆推广权益的合作，今年则是产品层面的收购，两者涉及的权益范围不同。此次交易完成后，亿帆医药的现有合作如何衔接，中国市场的推广、供货及相关人员安排是否调整，目前关联公司均没有公开的信息披露。从市场表现看，拜万戈也确实面临压力。据 Fierce Pharma 报道，2026 年上半年，该药全球销售额为 1.48 亿欧元，同比下降约 18%，其中包括中国市场集采带来的影响。 2024 年，瑞戈非尼进入第十批国采目录。年底开标结果显示，拜万戈未能进入，上海创诺制药、南京正大天晴、扬子江药业、科伦制药、齐鲁制药、江西科睿药业中选（见 MRCLUB 历史消息：分地盘！第十批国采官宣中选结果，来看下你们省份哪家供应？）。据媒体报道，中选仿制药最低价格折合每片仅 4.21 元，第十批国采已经于去年 4 月在各省陆续执标（见 MRCLUB 历史消息：第十批国采，9省市公布执标时间）。对于此次出售的原因，拜耳发言人解释，这是公司创新驱动增长战略的一部分，有助于进一步集中资源推进突破性创新。而买方格兰泰看重的，是成熟药品仍能带来的收益。按照其公告，在交易如期完成并全年并表的前提下，拜万戈预计可为公司 2027 年合并息税折旧摊销前利润（EBITDA）贡献最高约 1 亿欧元。这也符合格兰泰通过收购成熟药品增强盈利、支持创新研发的经营思路。格兰泰公司在公告中表示，此次收购是公司并购战略的最新推进。在此之前，这家公司已成功整合多款覆盖不同疾病领域的重要药品，包括拜耳耐必多（Nebido，十一酸睾酮）的全球权益，礼来希爱力（Cialis，他达拉非）在墨西哥、巴西和哥伦比亚的权益，阿斯利康可定（Crestor，瑞舒伐他汀）在欧洲的权益（英国和西班牙除外），以及耐信（Nexium，埃索美拉唑）的欧洲权益，以及阿斯利康 Vimovo（萘普生／埃索美拉唑复方制剂）美国和日本除外的全球权益、阿斯利康佐米格（Zomig，佐米曲普坦）的日本除外全球权益，以及从安斯泰来和 Acorda Therapeutics 手中收过来的 Qutenza 的全球权益。除药品资产收购外，今年早些时候，格兰泰还收购了 Grünenthal Meds 的全部股权。这家公司此前是格兰泰与协和麒麟国际（Kyowa Kirin International）成立的合资企业，负责其成熟药品组合的市场销售。2024 年，格兰泰还收购了美国公司 Valinor Pharma 及其产品 Movantik。格兰泰公司表示，自 2017 年以来，公司已在成功完成的并购交易中投入约 26 亿欧元。近日热点： 2026年全球药企50强前诺华中国总裁张颖，下一站公布！阿斯利康加速拓展管线布局医药代表备案学历问题，最新官方解读武田制药前总裁去世治理变相带金销售，14部门确定任务分工销售“回流药”，7家药企被查处诺和诺德，连签两个大单！ 50家药企年收将超百亿！医药行业重磅文件发布央视曝光“回流药”黑色产业链曾为辉瑞代表，她将出任安斯泰来首席合规官武田制药原总裁，下一站公布！诺和亮“新牌”，超5款超级重磅药品在后头中国10大民营药企公布！代表交流：医药代表的7个职业路线全球制药行业三大超级赛道医药代表职业规划路线图，你处于哪个阶段？最新职位：来拜耳中国上班！最新热招职位一览首药控股商业化启航，诚招英才最新药企内部招聘（9月21日更新）医药代表伴您成长！

2026-09-23

·微信

拜耳出售一款肿瘤新药

当地时间 9 月 21 日，Grünenthal（格兰泰）宣布与拜耳达成协议，以最高 3.75 亿欧元（约 4.3 亿美元）收购其用于特定晚期癌症的口服药物 Stivarga（瑞戈非尼）。此次收购需满足惯例成交条件，包括获得相关监管机构的批准。预计收购将于 2026 年底或 2027 年初完成。瑞戈非尼是一种口服多激酶抑制剂，适用于已接受过其他可用治疗或无法接受其他可用治疗的转移性结直肠癌、肝细胞癌和胃肠道间质瘤（GIST）患者。该药已在全球 90 多个市场获批上市。截图来源：Insight 数据库根据新闻稿，瑞戈非尼在欧盟的专利保护预计将持续到 2029 年，在美国则持续到 2030 年。但在中国失去独家销售权已经对销售额造成了影响，该药在 2026 年上半年的销售额下降了 18%，至 1.48 亿欧元。根据对拜耳公司向 Grünenthal 提供的相关信息的分析，并假设交易于 2026 年底或 2027 年初完成，且采用全年合并计算，瑞戈非尼可能对其截至 2027 年 12 月 31 日止年度的合并 EBITDA 产生高达约 1 亿欧元的积极影响。此次收购是 Grünenthal 并购战略的最新进展，此前该公司已成功整合了多种重要药物，包括拜耳男性性腺功能减退症药物 Nebido（十一酸睾酮）、治疗阿片类药物引起的便秘的药物 Movantik（纳洛西酮）等。值得一提的是，在出售瑞戈非尼之前，拜耳一直在持续出售成熟和非核心资产，同时把资本和研发资源集中到少数高增长创新药和核心业务上，包括抗感染药 Avelox（莫西沙星）、男性健康/激素替代产品 Nebido 等。来源：Insight 数据库加入读者交流群： —精彩回顾— 乙肝临床治愈王座之争进入决胜时刻 “全球首个”难治性肾病新药获批上市国产银屑病1类新药获批上市默沙东长效 RSV 单抗在中国获批上市干燥综合征，全球首个生物药在我国获批联系我们： wbfsh@staff.weibo.com

2026-09-23

·摩熵医药

3.75亿欧元！格兰泰收购拜耳抗癌药

9月21日，Grünenthal（格兰泰）宣布与拜耳达成协议，将以最高3.75亿欧元（约4.3亿美元）收购拜耳旗下抗癌药物Stivarga（瑞戈非尼）。截图来源：企业官网交易仍需满足惯例成交条件，包括获得相关监管机构批准，预计将于2026年底或2027年初完成。 01 3.75亿欧元，拿下一款成熟抗癌药瑞戈非尼是一款口服多激酶抑制剂，目前主要用于既往接受过其他可用治疗或无法接受其他治疗的部分晚期癌症患者，包括转移性结直肠癌、肝细胞癌和胃肠道间质瘤（GIST）。目前，该药已在全球90多个市场获批上市，累计已有超过100万名患者接受治疗。来源：摩熵医药全球药物研发数据库（查数据.找摩熵）从市场生命周期来看，瑞戈非尼已经是一款成熟产品。格兰泰尔披露，其在欧盟的专利保护预计持续至2029年，美国则预计持续至2030年。不过，产品在部分市场的独占期已经陆续受到影响。格兰泰尔预计，瑞戈非尼在交易完成后仍有望贡献可观的现金流，并预计在假设2026年底或2027年初完成交易、按全年并表的情况下，2027年度合并EBITDA最高可增加约1亿欧元。 02 格兰泰尔，持续加码成熟药并购对于格兰泰尔而言，这并不是一次孤立的资产收购。近年来，公司持续通过并购和产品授权扩充成熟药物组合，先后获得包括Nebido、Movantik等产品的相关权益，并通过并购进一步扩大商业化产品布局。截至目前，格兰泰尔自2017年以来已在并购交易上投入约26亿欧元。公司2025年实现营收约18亿欧元，调整后EBITDA达到5亿欧元。其当前的商业模式也较为明确：围绕已经验证市场需求的成熟药物，通过自身商业化、供应链和运营能力进一步释放产品价值。此次收购的瑞戈非尼，正符合这一思路——产品已经商业化多年，拥有成熟的临床应用基础和全球市场覆盖，同时距离欧美核心市场专利到期仍有一定时间窗口。 03 拜耳进一步聚焦核心创新业务对于拜耳而言，出售瑞戈非尼则体现了其持续进行业务组合调整的思路。 2026年，拜耳明确将资源重点放在肿瘤、心血管、神经系统和免疫等核心治疗领域的创新管线，同时推动高价值商业化产品的全球市场拓展。瑞戈非尼目前仍属于拜耳肿瘤产品组合的一部分，但随着产品逐步进入成熟期，其未来增长空间与创新管线相比存在差异。此次出售也意味着拜耳将进一步调整成熟产品与创新资产之间的资源配置。值得关注的是，拜耳并非简单收缩肿瘤业务，而是在持续引入新的创新资产。今年5月，拜耳宣布收购Perfuse Therapeutics，以获得处于II期临床阶段的PER-001，进一步补充眼科创新管线。一边出售成熟产品，一边加码创新管线，正在成为大型药企优化产品组合的重要路径。 END 本文为原创文章，转载请留言获取授权注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。点击阅读原文，申请摩熵医药企业版免费试用！

100 项与纳洛塞醇相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10375	-	A06AH03	DB09049

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
便秘	加拿大	Knight Therapeutics, Inc.	2015-08-27
阿片类药物引起的便秘	美国	Averitas Pharma, Inc.	2014-09-16

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
危重病	临床3期	美国	AstraZeneca PLC	2017-05-01
癌症疼痛	临床3期	美国	AstraZeneca PLC	2011-03-01
癌症疼痛	临床3期	澳大利亚	AstraZeneca PLC	2011-03-01
癌症疼痛	临床3期	比利时	AstraZeneca PLC	2011-03-01
癌症疼痛	临床3期	克罗地亚	AstraZeneca PLC	2011-03-01
癌症疼痛	临床3期	捷克	AstraZeneca PLC	2011-03-01
癌症疼痛	临床3期	德国	AstraZeneca PLC	2011-03-01
癌症疼痛	临床3期	匈牙利	AstraZeneca PLC	2011-03-01
癌症疼痛	临床3期	斯洛伐克	AstraZeneca PLC	2011-03-01
癌症疼痛	临床3期	西班牙	AstraZeneca PLC	2011-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04433390 (Pubmed \| Anaesth Crit Care Pain Med)	临床3期	术后肠梗阻	299	Naloxegol 12.5 mg followed by Naloxegol 25 mg	獵壓夢餘壓選淵製夢夢(醖鬱壓齋簾顧顧膚鹹遞) = 憲鹽鏇齋壓糧鬱範觸醖鏇顧鑰窪獵壓蓋夢簾艱 (構鏇構鹹獵鏇鑰遞糧繭, 69.3 ~ 93.5)	不佳	2025-04-01
				Placebo	獵壓夢餘壓選淵製夢夢(醖鬱壓齋簾顧顧膚鹹遞) = 膚構網網願鏇繭艱鬱製鏇顧鑰窪獵壓蓋夢簾艱 (構鏇構鹹獵鏇鑰遞糧繭, 70.0 ~ 95.8)
NCT03523520 (CTgov)	临床4期	阿片类药物引起的便秘	15	Methylnaltrexone Bromide 150 mg Oral Tablet (Methylnaltrexone Oral Tablets)	窪鏇顧襯襯網憲衊醖艱 = 簾鏇顧願選夢遞鹽醖繭簾醖襯憲醖觸築餘積憲 (鬱積膚鏇夢淵構顧齋繭, 廠網築鏇醖築醖齋築鬱 ~ 觸淵艱顧鏇鹹選壓淵憲) 更多	-	2024-09-19
				Methylnaltrexone Bromide 12 MG/0.6 ML Subcutaneous Solution [RELISTOR]_#1 (Methylnaltrexone Subcutaneous Injection)	窪鏇顧襯襯網憲衊醖艱 = 窪膚鬱鏇夢觸積衊網鹹簾醖襯憲醖觸築餘積憲 (鬱積膚鏇夢淵構顧齋繭, 窪壓糧範獵憲壓艱糧壓 ~ 願範糧鏇築製蓋蓋鬱蓋) 更多
NCT03235739 (CTgov)	临床4期	术后疼痛	136	Placebo	齋廠憲獵餘衊鬱鑰淵獵(鏇製獵醖壓衊簾範糧範) = 糧醖觸醖製齋襯膚鬱選範襯夢蓋鬱範鏇構艱網 (築築鑰淵選窪餘襯繭醖, 鑰艱願獵選餘積鏇艱範 ~ 獵觸鏇願範蓋齋遞築積) 更多	-	2023-09-05
NCT02977286 (CTgov)	临床4期	便秘	12	Polyethylene Glycols+Magnesium Citrate Oral Liquid Product+Bisacodyl 10 mg Suppository+Docusate Sodium 100 Mg oral capsule [Colace]+Naloxegol Oral Tablet+Senna 217 Mg Oral Tablet+Methylnaltrexone (Naloxegol Oral Tablet)	艱膚壓鹽鹹憲願願糧夢(獵糧壓獵壓淵鑰繭淵衊) = 糧醖蓋壓齋醖廠網醖鬱醖鏇膚積醖鹽廠鑰願製 (構糧繭願鹹遞積鹽願醖, 25) 更多	-	2023-02-16
				Placebo Oral Tablet+Magnesium Citrate Oral Liquid Product+Bisacodyl 10 mg Suppository+Docusate Sodium 100 Mg oral capsule [Colace]+Senna 217 Mg Oral Tablet+Methylnaltrexone (Placebo Oral Tablet)	艱膚壓鹽鹹憲願願糧夢(獵糧壓獵壓淵鑰繭淵衊) = 築獵鬱繭襯繭觸糧繭範醖鏇膚積醖鹽廠鑰願製 (構糧繭願鹹遞積鹽願醖, 25) 更多
NCT03638440 (NACASY, ESMO2020)	N/A	阿片类药物引起的便秘	-	Naloxegol	壓蓋壓襯網壓觸鹹積糧(構鹹醖範繭鬱鑰鬱網廠) = grade 1-2 壓餘築夢廠蓋簾範艱夢 (範醖窪餘鹹憲觸鬱鑰蓋 ) 更多	-	2020-09-17
ESMO2020	N/A	阿片类药物引起的便秘	126	Naloxegol	窪築繭齋願遞廠鹽顧遞(廠構製壓鏇鑰鬱鏇淵範) = 28 adverse reactions, mainly gastrointestinal, were observed in 15.1% of the patients (19/126), being 75% (21) mild, 17.9% (5) moderate and 7.1% (2) severe. Most adverse reactions (67.9%) appeared the first 15 days of treatment. 鹽齋製製醖壓築衊齋鑰 (壓醖艱鏇鑰廠製艱淵製 )	积极	2020-09-17
ASCO2020	N/A	阿片类药物引起的便秘	126	Naloxegol 25 mg/day	糧選糧憲鬱顧壓鹹積鬱(醖網製簾範鹹淵觸簾夢) = A total of 28 adverse reactions mainly gastrointestinal were observed in 15.1% of the patients (19/126), 75% (21) mild, 17.9% (5) moderate and 7.1% (2) severe. Most adverse reactions (67.9%) were observed the first 15 days of treatment with naloxegol. 構壓膚網願鏇鹹夢壓鏇 (顧構鑰衊鏇製憲構醖觸 )	积极	2020-05-25
				Naloxegol 12.5 mg/day
ESMO2019	N/A	阿片类药物引起的便秘	126	Naloxegol 12.5mg/day	夢襯顧簾襯構顧襯觸鬱(鏇製廠鬱遞壓網鑰遞範) = A total of 24 adverse reactions appeared in 13.5% of the patients (17/126) 網範衊獵鹽鑰窪積憲鏇 (觸範壓憲遞襯淵獵艱構 )	积极	2019-09-28
				Naloxegol 25mg/day
NCT02946580 (CTgov)	临床4期	便秘	53	naloxegol (MOVANTIK™ (Naloxegol))	衊顧齋糧鬱簾積簾繭膚(鏇鬱繭構繭醖願齋鏇簾) = 膚鏇鏇憲範構夢衊壓獵網膚鏇獵顧襯鹽壓遞衊 (淵鹹衊積鬱網衊鑰鏇願, 夢積襯齋鑰壓願選積鹽 ~ 襯製築醖遞選範顧鏇廠) 更多	-	2019-09-10
				sugar pill (Sugar Pill)	衊顧齋糧鬱簾積簾繭膚(鏇鬱繭構繭醖願齋鏇簾) = 鹹獵遞憲膚壓築淵壓觸網膚鏇獵顧襯鹽壓遞衊 (淵鹹衊積鬱網衊鑰鏇願, 鹹繭積窪積網夢齋積膚 ~ 蓋鹽膚觸衊積艱網窪鹹) 更多
NCT02839889 (CTgov)	临床4期	癌症疼痛 \| 疼痛 \| 阿片类药物引起的便秘 ... 更多	12	Placebo (Placebo)	膚遞選膚製壓積構築顧(糧鑰範鹹醖艱餘鹹鬱憲) = 築憲窪鹹範鏇遞蓋顧鬱鑰鏇鏇網襯餘襯顧膚窪 (鑰範網蓋選鑰糧觸淵憲, 獵鹹觸齋醖網鏇艱製窪 ~ 鏇廠願鏇鹹繭膚夢壓廠) 更多	-	2019-03-05
				Naloxegol (Naloxegol)	膚遞選膚製壓積構築顧(糧鑰範鹹醖艱餘鹹鬱憲) = 衊遞夢餘憲積簾襯淵鑰鑰鏇鏇網襯餘襯顧膚窪 (鑰範網蓋選鑰糧觸淵憲, 構鹽餘簾淵淵繭淵鹹壓 ~ 鏇繭醖壓鏇壓醖膚廠積) 更多